CoLucid names Thomas P. Mathers CEO

Wednesday, July 20, 2011 11:28 AM

CoLucid Pharmaceuticals, a privately held biopharmaceutical company, has named Thomas P. Mathers its chief executive officer.

Mathers has more than 19 years of executive management, sales and marketing experience in the life sciences and medical device industry. He also serves on the board of directors for the Biotechnology Industry Organization (BIO), and as chairman of Declion Pharmaceuticals, a company he co-founded. Previously, he served as president and CEO of Peptimmune.

"Tom will lead the CoLucid team in formulating our phase III development and commercialization plans for lasmiditan," said Art Pappas, chairman of the board of directors and managing partner at Pappas Ventures.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs